{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:23Z","timestamp":1791357443521,"version":"4.3.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s40263-020-00744-2","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T07:02:24Z","timestamp":1593068544000},"page":"773-784","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0683-6506","authenticated-orcid":false,"given":"Yves","family":"Dauvilliers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-2169","authenticated-orcid":false,"given":"Colin","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5147-4383","authenticated-orcid":false,"given":"Geert","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4755-7060","authenticated-orcid":false,"given":"Gert Jan","family":"Lammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Emsellem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Plazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence P.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jed","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Thorpy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"issue":"2","key":"744_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ccm.2010.02.014","volume":"31","author":"I Ahmed","year":"2010","unstructured":"Ahmed I, Thorpy M. Clinical features, diagnosis and treatment of narcolepsy. Clin Chest Med. 2010;31(2):371\u201381.","journal-title":"Clin Chest Med"},{"issue":"12","key":"744_CR2","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","volume":"30","author":"TI Morgenthaler","year":"2007","unstructured":"Morgenthaler TI, Kapur VK, Brown T, Swick TJ, Alessi C, Aurora RN, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705\u201311.","journal-title":"Sleep"},{"key":"744_CR3","doi-asserted-by":"publisher","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","volume":"3","author":"BR Kornum","year":"2017","unstructured":"Kornum BR, Knudsen S, Ollila HM, Pizza F, Jennum PJ, Dauvilliers Y, et al. Narcolepsy. Nat Rev Dis Primers. 2017;3:16100.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"744_CR4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nrneurol.2014.97","volume":"10","author":"Y Dauvilliers","year":"2014","unstructured":"Dauvilliers Y, Siegel JM, Lopez R, Torontali ZA, Peever JH. Cataplexy\u2014clinical aspects, pathophysiology and management strategy. Nat Rev Neurol. 2014;10(7):386\u201395.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"744_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/sleep\/25.2.197","volume":"25","author":"MH Silber","year":"2002","unstructured":"Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep. 2002;25(2):197\u2013202.","journal-title":"Sleep"},{"issue":"4","key":"744_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.sleep.2008.05.009","volume":"10","author":"WT Longstreth Jr","year":"2009","unstructured":"Longstreth WT Jr, Ton TG, Koepsell T, Gersuk VH, Hendrickson A, Velde S. Prevalence of narcolepsy in King County, Washington, USA. Sleep Med. 2009;10(4):422\u20136.","journal-title":"Sleep Med"},{"issue":"8","key":"744_CR7","doi-asserted-by":"publisher","first-page":"805","DOI":"10.5664\/jcsm.2926","volume":"9","author":"B Frauscher","year":"2013","unstructured":"Frauscher B, Ehrmann L, Mitterling T, Gabelia D, Gschliesser V, Brandauer E, et al. Delayed diagnosis, range of severity, and multiple sleep comorbidities: a clinical and polysomnographic analysis of 100 patients of the innsbruck narcolepsy cohort. J Clin Sleep Med. 2013;9(8):805\u201312.","journal-title":"J Clin Sleep Med"},{"key":"744_CR8","volume-title":"International classification of sleep disorders","author":"American Academy of Sleep Medicine","year":"2014","unstructured":"American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien: American Academy of Sleep Medicine; 2014.","edition":"3"},{"key":"744_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.sleep.2016.07.010","volume":"24","author":"J Black","year":"2016","unstructured":"Black J, Swick T, Bogan R, Lai C, Carter LP. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. Sleep Med. 2016;24:57\u201362.","journal-title":"Sleep Med"},{"issue":"2","key":"744_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1124\/jpet.118.248120","volume":"366","author":"MG Baladi","year":"2018","unstructured":"Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, et al. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2018;366(2):367\u201376.","journal-title":"J Pharmacol Exp Ther"},{"key":"744_CR11","unstructured":"Sunosi\u00ae (solriamfetol) tablets prescribing information. Palo Alto: Jazz Pharmaceuticals, Inc; 2019."},{"key":"744_CR12","unstructured":"Sunosi\u00ae (solriamfetol) tablets summary of product characteristics. Dublin: Jazz Pharmaceuticals Ireland Ltd; 2020."},{"issue":"7","key":"744_CR13","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.5665\/sleep.5968","volume":"39","author":"C Ruoff","year":"2016","unstructured":"Ruoff C, Swick TJ, Doekel R, Emsellem HA, Feldman NT, Rosenberg R, et al. Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study. Sleep. 2016;39(7):1379\u201387.","journal-title":"Sleep"},{"issue":"3","key":"744_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/ana.25423","volume":"85","author":"MJ Thorpy","year":"2019","unstructured":"Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359\u201370.","journal-title":"Ann Neurol"},{"key":"744_CR15","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Narcolepsy. Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Narcolepsy. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American Psychiatric Association; 2013. p. 372\u2013378.","edition":"5"},{"issue":"5","key":"744_CR16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/S0013-4694(97)00010-2","volume":"103","author":"K Doghramji","year":"1997","unstructured":"Doghramji K, Mitler MM, Sangal RB, Shapiro C, Taylor S, Walsleben J, et al. A normative study of the maintenance of wakefulness test (MWT). Electroencephalogr Clin Neurophysiol. 1997;103(5):554\u201362.","journal-title":"Electroencephalogr Clin Neurophysiol"},{"issue":"6","key":"744_CR17","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540\u20135.","journal-title":"Sleep"},{"issue":"8","key":"744_CR18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.5665\/sleep.4908","volume":"38","author":"F Pizza","year":"2015","unstructured":"Pizza F, Vandi S, Iloti M, Franceschini C, Liguori R, Mignot E, et al. Nocturnal sleep dynamics identify narcolepsy type 1. Sleep. 2015;38(8):1277\u201384.","journal-title":"Sleep"},{"issue":"9","key":"744_CR19","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.sleep.2015.05.013","volume":"16","author":"RK Bogan","year":"2015","unstructured":"Bogan RK, Feldman N, Emsellem HA, Rosenberg R, Lu Y, Bream G, et al. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med. 2015;16(9):1102\u20138.","journal-title":"Sleep Med"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00744-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-020-00744-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00744-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:13:34Z","timestamp":1624580014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-020-00744-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00744-2","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,25]]},"assertion":[{"value":"25 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Jazz Pharmaceuticals. Jazz Pharmaceuticals has worldwide development, manufacturing, and commercialization rights to solriamfetol, excluding certain jurisdictions in Asia. SK Biopharmaceuticals, the discoverer of the compound (also known as SKL-N05), maintains rights in 12 Asian markets, including Korea, China, and Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yves Dauvilliers has received consultancy fees and\/or honoraria and has been a speakers\u2019 bureau member and\/or an advisory board participant for UCB Pharma, Bioprojet, Theranexus, Flamel, Harmony Biosciences, Takeda, Idorsia, and Jazz Pharmaceuticals. Colin Shapiro has received research funding from the National Institutes of Health and the Canadian Institutes of Health Research and has served on the speakers\u2019 bureau for Jazz Pharmaceuticals. Geert Mayer has received honoraria from the Paul Ehrlich Institute, Germany; has served on the speakers\u2019 bureau for UCB Pharma, Sanofi, and Bioprojet; and is a board member of the International REM Sleep Behavior Study Group. Gert Jan Lammers has received consultancy fees and\/or honoraria and has been a speakers\u2019 bureau member and\/or an advisory board participant for UCB Pharma, Bioprojet, Theranexus, and Jazz Pharmaceuticals. Helene Emsellem has received consultancy fees, honoraria, and\/or has been a speakers\u2019 bureau member and advisory board participant for Jazz Pharmaceuticals and Vanda Pharmaceuticals; has received research funding from Jazz Pharmaceuticals, Vanda Pharmaceuticals, Eisai, Flamel (Avadel), Balance Therapeutics, Merck & Co, NightBalance, Novartis, Philips Respironics, Idorsia Pharmaceuticals, and Harmony Biosciences; and is a board member of the National Sleep Foundation. Giuseppe Plazzi has participated in advisory boards for UCB, Bioprojet, and Jazz Pharmaceuticals. Dan Chen, Lawrence P. Carter, and Lawrence Lee are employees of Jazz Pharmaceuticals who, in the course of this employment, have received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals plc. Jed Black is a part-time employee of Jazz Pharmaceuticals and shareholder of Jazz Pharmaceuticals plc. Michael J. Thorpy has received research\/grant support and consultancy and speakers\u2019 bureau fees from Jazz Pharmaceuticals; research funding from Flamel; consultancy and speakers\u2019 bureau fees from Merck & Co., Inc., and Cephalon, Inc. (now Teva Pharmaceutical Industries, Ltd); and consultancy fees from Harmony Biosciences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}